Patents by Inventor Taekyu Lee

Taekyu Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED INDOLE MCL-1 INHIBITORS
    Publication number: 20230330099
    Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: December 9, 2022
    Publication date: October 19, 2023
    Inventors: Taekyu Lee, James C. Tarr, KyuOk Jeon, James M. Salovich, Subrata Shaw, Nagarathanam Veerasamy, Kwangho Kim, Plamen P. Christov, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik, Zhiguo Bian
  • Substituted indole Mcl-1 inhibitors
    Patent number: 11596639
    Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: March 7, 2023
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, James C. Tarr, KyuOk Jeon, James M. Salovich, Subrata Shaw, Nagarathanam Veerasamy, Kwangho Kim, Plamen P. Christov, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik, Zhiguo Bian
  • SUBSTITUTED INDOLE MCL-1 INHIBITORS
    Publication number: 20230039309
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: November 4, 2021
    Publication date: February 9, 2023
    Inventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20230026466
    Abstract: Isoquinolmone compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
    Type: Application
    Filed: November 8, 2020
    Publication date: January 26, 2023
    Inventors: Taekyu Lee, Kevin B. Teuscher, Jianhua Tian, Kenneth M. Meyers, Somenath Chowdhury, Stephen W. Fesik
  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20230012362
    Abstract: Isoquinolinone compounds and derivatives inhibit WDRS and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
    Type: Application
    Filed: October 24, 2019
    Publication date: January 12, 2023
    Inventors: Taekyu Lee, Joseph R. Alvarado, Jianhua Tian, Kenneth M. Meyers, Changho Han, Jonathan J. Mills, Kevin B. Teuscher, Shaun R. Stauffer, Stephen W. Fesik
  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20220242849
    Abstract: Quinazolin-4(3H)-one, 2,3-dihydroquinazolin-4(1H)-one, 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one, and 3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione compounds and derivatives inhibit WDR5 and associated protein-protein interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.
    Type: Application
    Filed: June 4, 2020
    Publication date: August 4, 2022
    Inventors: Taekyu Lee, Changho Han, Jonathan J. Mills, Kevin B. Teuscher, Jianhua Tian, Kenneth M. Meyers, Somenath Chowdhury, Stephen W. Fesik
  • Substituted indole Mcl-1 inhibitors
    Patent number: 11208415
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: December 28, 2021
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
  • SUBSTITUTED INDOLE MCL-1 INHIBITORS
    Publication number: 20210283138
    Abstract: The present disclosure provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: March 3, 2017
    Publication date: September 16, 2021
    Inventors: Taekyu Lee, James C. Tarr, KyuOk Jeon, James M. Salovich, Subrata Shaw, Nagarathanam Veerasamy, Kwangho Kim, Plamen P. Christov, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik, Zhiguo Bian
  • Substituted indole Mcl-1 inhibitors
    Patent number: 10954193
    Abstract: The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: March 23, 2021
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, Kwangho Kim, Plamen P. Christov, Johannes Belmar, Jason P. Burke, Edward T. Olejniczak, Stephen W. Fesik
  • Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors
    Patent number: 10844032
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: November 24, 2020
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, Nicholas F. Pelz, Johannes Belmar, Zhiguo Bian, Edward T. Olejniczak, Stephen W. Fesik, Brian A. Chauder
  • WDR5 inhibitors and modulators
    Patent number: 10844044
    Abstract: Described are imino-azacycle-benzamide compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: November 24, 2020
    Assignee: Vanderbilt University
    Inventors: Joseph R. Alvarado, Shaun R. Stauffer, Rocco D. Gogliotti, Changho Han, Kenneth M. Meyers, Jianhua Tian, Jonathan D. Macdonald, Stephen W. Fesik, Taekyu Lee
  • WDR5-MLL1 inhibitors and modulators
    Patent number: 10807959
    Abstract: Benzamides and picolinamides that are meta-substituted with imino-, guanidino-, or heterocycle-containing groups disrupt the WDR5-MLL1 protein-protein interaction, and have use in pharmaceutical compositions and in treating proliferative disorders and conditions in a subject, such as cancer.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: October 20, 2020
    Assignee: Vanderbilt University
    Inventors: Rocco D. Gogliotti, Shaun R. Stauffer, KyuOk Jeon, James M. Salovich, Jonathan D. Macdonald, Jonathan J. Mills, Kenneth M. Meyers, Joseph R. Alvarado, Changho Han, Stephen W. Fesik, Taekyu Lee
  • SUBSTITUTED INDOLE MCL-1 INHIBITORS
    Publication number: 20200140447
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: November 19, 2019
    Publication date: May 7, 2020
    Inventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
  • WDR5 INHIBITORS AND MODULATORS
    Publication number: 20200102288
    Abstract: Described are imino-azacycle-benzamide compounds compounds that inhibit WDR5 and associated protein-protein interactions, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.
    Type: Application
    Filed: June 14, 2019
    Publication date: April 2, 2020
    Inventors: Joseph R. Alvarado, Shaun R. Stauffer, Rocco D. Gogliotti, Changho Han, Kenneth M. Meyers, Jianhua Tian, Jonathan D. Macdonald, Stephen W. Fesik, Taekyu Lee
  • WDR5-MLL1 INHIBITORS AND MODULATORS
    Publication number: 20200055824
    Abstract: Benzamides and picolinamides that are meta-substituted with imino-, guanidino-, or heterocycle-containing groups disrupt the WDR5-MLL1 protein-protein interaction, and have use in pharmaceutical compositions and in treating proliferative disorders and conditions in a subject, such as cancer.
    Type: Application
    Filed: August 16, 2019
    Publication date: February 20, 2020
    Inventors: Rocco D. Gogliotti, Shaun R. Stauffer, KyuOk Jeon, James M. Salovich, Jonathan D. Macdonald, Jonathan J. Mills, Kenneth M. Meyers, Joseph R. Alvarado, Changho Han, Stephen W. Fesik, Taekyu Lee
  • Substituted indole Mcl-1 inhibitors
    Patent number: 10533010
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: January 14, 2020
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, Zhiguo Bian, Johannes Belmar, Plamen P. Christov, Nicholas F. Pelz, Subrata Shaw, Kwangho Kim, James C. Tarr, Edward T. Olejniczak, Bin Zhao, Stephen W. Fesik
  • SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS
    Publication number: 20180312485
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Application
    Filed: July 2, 2018
    Publication date: November 1, 2018
    Inventors: Taekyu Lee, Nicholas F. Pelz, Johannes Belmar, Zhiguo Bian, Edward T. Olejniczak, Stephen W. Fesik, Brian A. Chauder
  • Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
    Patent number: 10093640
    Abstract: The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: October 9, 2018
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, Nicholas F. Pelz, Johannes Belmar, Zhiguo Bian, Edward T. Olejniczak, Stephen W. Fesik, Brian A. Chauder
  • SUBSTITUTED INDOLE MCL-1 INHIBITORS
    Publication number: 20180258039
    Abstract: The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.
    Type: Application
    Filed: May 10, 2018
    Publication date: September 13, 2018
    Inventors: Taekyu Lee, Kwangho Kim, Plamen P. Christov, Johannes Belmar, Jason P. Burke, Edward T. Olejniczak, Stephen W. Fesik
  • Substituted indole Mcl-1 inhibitors
    Patent number: 10005728
    Abstract: The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: June 26, 2018
    Assignee: Vanderbilt University
    Inventors: Taekyu Lee, Kwangho Kim, Plamen P. Christov, Johannes Belmar, Jason P. Burke, Edward T. Olejniczak, Stephen W. Fesik